CYP2D6 and breast carcinoma: Ultrarapid CYP2D6 metabolizers had a significantly higher breast cancer–specific mortality (HR, 4.52; 95% CI, 1.42 to 14.37) compared with normal metabolizers after adjusting for all variables listed in Table 1.